The podcast features a discussion about the studies that have been done on psychedelics for treating addiction, anxiety, depression, and end-of-life care. The guest talks about the surprising results of some of these studies, including one from 2006 by Johns Hopkins.
Dr. Stephen Ross discusses the potential therapeutic uses of psilocybin, including depression and anxiety associated with a cancer diagnosis, smoking cessation, and alcoholism. Though promising results have been seen in pilot studies, large randomized trials are needed for FDA approval.
Studies suggest that kava, a natural supplement derived from Pacific island cultures, produces a potent anxiolytic effect and reduces symptoms of anxiety and depression.
Dr. D'Amanda Kennedy explains how to start healing anxiety through guided therapeutic experiences with ketamine, MDMA, or psilocybin which can help to reconnect and repair the original cause of anxiety. She also discusses a series of simple steps and coping mechanisms to deal with anxiety like therapy, breath work, meditation, exercise, etc.
The proportion of CBD to THC is more linked to the cause or treatment of psychosis, rather than the use of cannabis itself. Clinical trials for a seizure disorder called Dravet's Syndrome, which causes seizures in children, are currently being conducted.